Interaction of nanoparticles with immunocompetent cells: nanosafety considerations.

Intentional delivery of high doses of nanoparticle-based drugs or diagnostic/imaging systems sets a new scenario in safety evaluation, compared with the environmentally borne unintentional exposure to engineered nanoparticles. Intravenously administered nanomedicines immediately interact with blood components such as serum proteins, changing their own characteristics and consequently the features of their interaction with cells and tissues. Of major importance is the interaction of nanomedicines with the immune system, which is essential in the recognition and elimination of foreign dangerous agents. Nanomedicines need to avoid immune recognition in order to reach their therapeutic target and display their effect, should not trigger defensive mechanisms that can damage the body tissues (e.g., complement activation or inflammation) and should not interfere with immunocompetent cells in order to avoid promoting immune-related diseases. This review will briefly cover these issues, and propose some knowledge-based approaches for future 'safe-by-design' nanomedicines.

[1]  D. Irvine,et al.  Particulate vaccines: on the quest for optimal delivery and immune response. , 2011, Drug discovery today.

[2]  Sven Frokjaer,et al.  Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. , 2005, International journal of pharmaceutics.

[3]  F. Martinon.  Update on Biology: Uric Acid and the Activation of Immune and Inflammatory Cells , 2010, Current rheumatology reports.

[4]  A. Judge,et al.  Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  M. Ozkan,et al.  Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy , 2011, Journal of Translational Medicine.

[6]  Wei-Hsin Hsu,et al.  Novel geometry type of nanocarriers mitigated the phagocytosis for drug delivery. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Albert Duschl,et al.  The suitability of different cellular in vitro immunotoxicity and genotoxicity methods for the analysis of nanoparticle-induced events , 2010, Nanotoxicology.

[8]  David A. Anderson,et al.  Virus-like particles: Passport to immune recognition , 2006, Methods.

[9]  Catrin Albrecht,et al.  Cellular responses to nanoparticles: Target structures and mechanisms , 2007 .

[10]  John D Lambris,et al.  Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? , 2010, Trends in immunology.

[11]  Young-Ran Lee,et al.  Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen , 2010, Archives of pharmacal research.

[12]  H. Tsukada,et al.  T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. , 2010, International journal of pharmaceutics.

[13]  P. Cresswell,et al.  Enhanced and prolonged cross‐presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles , 2006, Immunology.

[14]  A. Zychlinsky,et al.  NETs: a new strategy for using old weapons. , 2009, Trends in immunology.

[15]  Hans P. Merkle,et al.  Phagocytosis and Phagosomal Fate of Surface-Modified Microparticles in Dendritic Cells and Macrophages , 2003, Pharmaceutical Research.

[16]  T. Ishida,et al.  Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[17]  Christian Mühlfeld,et al.  Translocation and cellular entering mechanisms of nanoparticles in the respiratory tract. , 2008, Swiss medical weekly.

[18]  G. Tosi,et al.  PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid. , 2010, Biomaterials.

[19]  H. Merkle,et al.  Competitive adsorption of serum proteins at microparticles affects phagocytosis by dendritic cells. , 2003, Biomaterials.

[20]  Richard O'Kennedy,et al.  Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells. , 2007, Drug discovery today.

[21]  Judith Klein-Seetharaman,et al.  Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation. , 2010, Nature nanotechnology.

[22]  S Moein Moghimi,et al.  Complement: alive and kicking nanomedicines. , 2009, Journal of biomedical nanotechnology.

[23]  Mark M Davis,et al.  A prescription for human immunology. , 2008, Immunity.

[24]  Vasso Apostolopoulos,et al.  Pathogen recognition and development of particulate vaccines: does size matter? , 2006, Methods.

[25]  S Moein Moghimi,et al.  Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. , 2010, ACS nano.

[26]  Albert Duschl,et al.  Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects , 2011, Particle and Fibre Toxicology.

[27]  I. Srivastava,et al.  Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens , 2011, Expert review of vaccines.

[28]  Scott E McNeil.  Challenges for nanoparticle characterization. , 2011, Methods in molecular biology.

[29]  Marina A Dobrovolskaia,et al.  Evaluation of nanoparticle immunotoxicity. , 2009, Nature nanotechnology.

[30]  Jürgen Groll,et al.  Phagocytosis independent extracellular nanoparticle clearance by human immune cells. , 2010, Nano letters.

[31]  Robert Langer,et al.  Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. , 2009, Biomaterials.

[32]  L. Moldawer,et al.  INTERLEUKIN‐1 AND INTERLEUKIN‐1 ANTAGONISM IN SEPSIS, SYSTEMIC INFLAMMATORY RESPONSE SYNDROME, AND SEPTIC SHOCK , 1995, Shock.

[33]  Hans Bouwmeester,et al.  Characterization of translocation of silver nanoparticles and effects on whole-genome gene expression using an in vitro intestinal epithelium coculture model. , 2011, ACS nano.

[34]  Ji-Ho Park,et al.  Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. , 2009, Biomaterials.

[35]  Robert N Grass,et al.  Exposure of engineered nanoparticles to human lung epithelial cells: influence of chemical composition and catalytic activity on oxidative stress. , 2007, Environmental science & technology.

[36]  Kai Yang,et al.  In vivo pharmacokinetics, long-term biodistribution, and toxicology of PEGylated graphene in mice. , 2011, ACS nano.

[37]  P. Couvreur,et al.  Nanocarriers’ entry into the cell: relevance to drug delivery , 2009, Cellular and Molecular Life Sciences.

[38]  M. Pangburn,et al.  Complement control protein factor H: the good, the bad, and the inadequate. , 2010, Molecular immunology.

[39]  F. Re,et al.  Cutting Edge: Inflammasome Activation by Alum and Alum’s Adjuvant Effect Are Mediated by NLRP31 , 2008, The Journal of Immunology.

[40]  Kinam Park.  To PEGylate or not to PEGylate, that is not the question. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[41]  C. Dinarello,et al.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. , 2011, Blood.

[42]  R. Amal,et al.  Stabilization of magnetic iron oxide nanoparticles in biological media by fetal bovine serum (FBS). , 2011, Langmuir : the ACS journal of surfaces and colloids.

[43]  H. Merkle,et al.  Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[44]  G. Trinchieri,et al.  Type I interferon: friend or foe? , 2010, The Journal of experimental medicine.

[45]  Marina A Dobrovolskaia,et al.  Nanoparticles and the immune system. , 2010, Endocrinology.

[46]  M. Tallman,et al.  Intravascular clotting activation and bleeding in patients with hematologic malignancies. , 2004, Reviews in clinical and experimental hematology.

[47]  Bengt Fadeel,et al.  Close encounters of the small kind: adverse effects of man-made materials interfacing with the nano-cosmos of biological systems. , 2010, Annual review of pharmacology and toxicology.

[48]  M. Hope,et al.  Immunogenicity and Rapid Blood Clearance of Liposomes Containing Polyethylene Glycol-Lipid Conjugates and Nucleic Acid , 2005, Journal of Pharmacology and Experimental Therapeutics.

[49]  F. Martinon,et al.  The inflammasomes: guardians of the body. , 2009, Annual review of immunology.

[50]  Sandra L. Schmid,et al.  Regulated portals of entry into the cell , 2003, Nature.

[51]  Zhengrong Cui,et al.  Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses , 2010, Expert review of vaccines.

[52]  Albert Duschl,et al.  Time evolution of the nanoparticle protein corona. , 2010, ACS nano.

[53]  Iseult Lynch,et al.  Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.

[54]  Sudipta Seal,et al.  Bio‐distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice , 2013, Environmental toxicology.

[55]  J. Tschopp,et al.  Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β , 2010, Proceedings of the National Academy of Sciences.

[56]  M. Akashi,et al.  Comparative activity of biodegradable nanoparticles with aluminum adjuvants: antigen uptake by dendritic cells and induction of immune response in mice. , 2011, Immunology letters.

[57]  A. Krieg,et al.  Toll‐like receptors 7, 8, and 9: linking innate immunity to autoimmunity , 2007, Immunological reviews.

[58]  Kenneth A. Dawson,et al.  Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.

[59]  M. Olivo,et al.  Critical parameters in the pegylation of gold nanoshells for biomedical applications: An in vitro macrophage study , 2009, Journal of drug targeting.

[60]  Yong Zhao,et al.  Enzymatic degradation of multiwalled carbon nanotubes. , 2011, The journal of physical chemistry. A.

[61]  Huub Schellekens,et al.  Immunological Risk of Injectable Drug Delivery Systems , 2009, Pharmaceutical Research.

[62]  M. Dobrovolskaia,et al.  Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.